이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Immunocore Holdings 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bahija Jallal

최고 경영자

US$11.7m

총 보상

CEO 급여 비율	6.3%
CEO 임기	5.7yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	5yrs

최근 관리 업데이트

Recent updates

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Sep 19

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Aug 12

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

Jul 24

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Jun 16

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

May 11

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Apr 05

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Jan 22

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Jan 21

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Dec 18

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

May 08

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16

Immunocore: Attractive Commercial-Stage Biopharma

Oct 05

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Aug 12

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Aug 10

Immunocore to raise $140M in private placement financing

Jul 18

CEO 보상 분석

Bahija Jallal 의 보수는 Immunocore Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$55m
Mar 31 2024	n/a	n/a	-US$60m
Dec 31 2023	US$12m	US$735k	-US$55m
Sep 30 2023	n/a	n/a	-US$66m
Jun 30 2023	n/a	n/a	-US$61m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$1m	US$700k	-US$53m
Sep 30 2022	n/a	n/a	-US$62m
Jun 30 2022	n/a	n/a	-US$112m
Mar 31 2022	n/a	n/a	-US$156m
Dec 31 2021	US$35m	US$700k	-US$180m
Sep 30 2021	n/a	n/a	-US$150m
Jun 30 2021	n/a	n/a	-US$139m
Mar 31 2021	n/a	n/a	-US$116m
Dec 31 2020	US$1m	n/a	-US$101m

보상 대 시장: Bahija 의 총 보상 ($USD 11.68M )은 US 시장( $USD 5.67M ).

보상과 수익: 회사가 수익성이 없는 동안 Bahija 의 보상이 증가했습니다.

CEO

Bahija Jallal (63 yo)

5.7yrs

테뉴어

US$11,678,834

보상

Dr. Bahija Jallal, Ph.D. serves as Director of Outpace Bio, Inc. from March 2023. She serves as Chief Executive Officer and Director of Immunocore Holdings plc (formerly known as Immunocore Holdings Limite...

리더십 팀

이름	위치	테뉴어	보상	소유권
Bahija Jallal	CEO & Executive Director	5.7yrs	US$11.68m	데이터 없음
Brian Di Donato	Executive VP	4.4yrs	US$3.35m	0.038% $ 603.9k
Tina Leger	Chief Human Resources Officer	2.6yrs	US$1.04m	0% $ 0
David Berman	Executive Vice President of Research & Development	5.7yrs	US$4.40m	0% $ 0
John Trainer	SVP & Chief Operating Officer	less than a year	데이터 없음	데이터 없음
John Goll	SVP, Finance & Chief Accounting Officer	less than a year	데이터 없음	데이터 없음
Annelise Vuidepot	Senior VP	no data	데이터 없음	데이터 없음
Sean Buckley	VP & Chief Information Officer	less than a year	데이터 없음	데이터 없음
Clayton Robertson	Head of Investor Relations	no data	데이터 없음	데이터 없음
Lily Hepworth	Senior VP	3.7yrs	데이터 없음	데이터 없음
Elizabeth Jobes	Chief Compliance Officer	less than a year	데이터 없음	데이터 없음
Sébastien Desprez	Vice President of Communications	2.7yrs	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: IMCR 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bahija Jallal	CEO & Executive Director	5.7yrs	US$11.68m	데이터 없음
John Bell	Independent Non-Executive Chairman	9.5yrs	US$416.99k	0.027% $ 422.3k
Kristine Peterson	Independent Non-Executive Director	6.8yrs	US$389.49k	0% $ 0
Robert Perez	Independent Non-Executive Director	5yrs	데이터 없음	데이터 없음
Roy Steven Herbst	Independent Non-Executive Director	3.7yrs	US$386.99k	0% $ 0
Peter Ratcliffe	Independent Non-Executive Director	3.8yrs	US$384.49k	0.00067% $ 10.5k
Ranjeev Krishana	Director	less than a year	데이터 없음	데이터 없음
Travis Coy	Independent Non-Executive Director	5yrs	데이터 없음	데이터 없음
Siddharth Kaul	Independent Non-Executive Director	2.3yrs	US$386.99k	0% $ 0

5.0yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: IMCR 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

Immunocore Holdings 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Board Member notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Recent updates

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Immunocore Presents Phase 1 Data of Brenetafusp, an Immtac Bispecific Targeting Prame, in Patients with Ovarian Cancer

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Consensus estimates of losses per share improve by 26%

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Second quarter 2024 earnings: EPS exceeds analyst expectations

Immunocore Holdings plc to Report Q2, 2024 Results on Aug 08, 2024

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

New major risk - Revenue and earnings growth

Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Now 20% undervalued after recent price drop

Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma

Now 20% undervalued after recent price drop

Consensus EPS estimates fall by 26%, revenue upgraded

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.43 loss in 1Q 2023)

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

CEO & Director notifies of intention to sell stock

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates upgraded to UK£0.80 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Head of Research & Development notifies of intention to sell stock

New major risk - Revenue and earnings growth

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

CEO & Director notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates fall by 14%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

No longer forecast to breakeven

Consensus EPS estimates fall by 153%, revenue upgraded

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus estimates of losses per share improve by 10%

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Consensus forecasts updated

Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million.

Consensus forecasts updated

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Consensus revenue estimates increase by 27%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Immunocore: Attractive Commercial-Stage Biopharma

Consensus revenue estimates increase by 50%

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Second quarter 2022 earnings: Revenues exceed analyst expectations